Novo Nordisk A/S – Analysts’ Recommendations and Stock Price Forecast (2026)
Consensus Rating
Based on 21 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of “Hold.” Out of the 21 analysts, 1 has given a sell rating, 15 have given a hold rating, and 5 have given a buy rating for NVO.
Consensus Price Target
According to the 21 analysts’ twelve-month price targets for Novo Nordisk A/S, the average price target is $65.81. The highest price target for NVO is $175.00, while the lowest price target for NVO is $40.00. The average price target represents a forecasted upside of 39.42% from the current price of $47.21.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst’s rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock’s consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat’s consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat’s consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NVO and Related Stocks
Enter your email address to receive the latest news and analysts’ ratings for Novo Nordisk A/S and its competitors.
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying “STOP” to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
NVO Analyst Ratings Over Time
NVO Analyst Recommendations By Month
The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
NVO Price Targets by Month
The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table
Novo Nordisk A/S Stock vs. The Competition
Recent Analyst Forecasts and Stock Ratings
Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:16 AM ET.
Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 4, 2026. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.
Novo Nordisk A/S
Bull Case
Here are some ways that investors could benefit from investing in Novo Nordisk:
- Recent earnings per share (EPS) of $1.03 indicates strong profitability, showcasing the company’s ability to generate earnings relative to its share price.
- The company reported a substantial revenue of $10.85 billion for the quarter, reflecting robust sales performance and market demand for its products.
- With a return on equity of over 63%, Novo Nordisk demonstrates effective management in generating profits from shareholders’ equity, which is a positive indicator for potential investors.
- Analysts forecast an EPS of 3.39 for the current year, suggesting expected growth in earnings, which could lead to an increase in stock value.
- The current stock price is around $65.56, which is considered reasonable given the company’s strong financial metrics and growth potential.
Novo Nordisk A/S
Bear Case
Investors should be bearish about investing in Novo Nordisk for these reasons:
- Recent downgrades from several analysts, including a “strong sell” rating from Zacks Research, may indicate concerns about the company’s future performance.
- Weiss Ratings has reiterated a “sell” rating, suggesting that some analysts believe the stock may not perform well in the near term.
- Despite a strong revenue report, the competitive landscape in the pharmaceutical industry, particularly in diabetes care, poses risks to market share and profitability.
- Market sentiment appears mixed, with a consensus rating of “Hold” from analysts, indicating uncertainty about the stock’s future performance.
- Recent changes in institutional holdings, including significant sell-offs, could signal a lack of confidence among large investors in the company’s prospects.
NVO Forecast – Frequently Asked Questions
According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $65.81, with a high forecast of $175.00 and a low forecast of $40.00.
21 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Novo Nordisk A/S in the last year. There is currently 1 sell rating, 15 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “hold” NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
According to analysts, Novo Nordisk A/S’s stock has a predicted upside of 39.42% based on their 12-month stock forecasts.
Over the previous 90 days, Novo Nordisk A/S’s stock had 2 upgrades and 1 downgrade by analysts.
Analysts like Novo Nordisk A/S less than other “healthcare” companies. The consensus rating score for Novo Nordisk A/S is 2.19 while the average consensus rating score for “healthcare” companies is 2.30. Learn more on how NVO compares to other companies.
This page (NYSE:NVO) was last updated on 8/10/2026 by .
From Our Partners
